Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: a systematic review and meta-analysis.

Jun Liu; Yanjun Jia; Xiaolin LI; Ruixia XU; Chenggang Zhu; Yuanlin Guo; Naqiong WU; Jianjun LI

Return

Serum interleukin-10 levels and adverse events in patients with acute coronary syndrome: a systematic review and meta-analysis.

Author: Jun LIU ¹ ; Yanjun JIA ¹ ; Xiaolin LI ¹ ; Ruixia XU ¹ ; Chenggang ZHU ¹ ; Yuanlin GUO ¹ ; Naqiong WU ¹ ; Jianjun LI ²
Author Information

1. Division of Dyslipidemia, Cardiovascular Medicine, Fu Wai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China.
2. Division of Dyslipidemia, Cardiovascular Medicine, Fu Wai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100037, China. Email: lijianjun938@yahoo.com.
Publication Type:Journal Article
MeSH: Acute Coronary Syndrome; blood; Humans; Interleukin-10; blood
From: Chinese Medical Journal 2014;127(1):150-156
CountryChina
Language:English
Abstract:
BACKGROUNDSeveral studies investigating the prognostic utility of interleukin-10 (IL-10) in patients with acute coronary syndrome (ACS) have provided conflicting findings. The aim of the study was to assess the existing evidence regarding association between serum IL-10 levels and adverse events.
METHODSLiterature search was performed in PubMed, EMBASE, and Cochrane Trials Register databases from their inception to September 30, 2012. In addition, reference lists of the included articles and their related citations in PubMed were also reviewed for additional pertinent studies.
RESULTSA total of 12 eligible studies comprising a total of 5882 patients were identified. The pooled relative risks for both studies reporting the risk estimates by IL-10 categories and studies reporting the risk estimates by unit IL-10 indicated an association between high IL-10 levels and adverse events. Sensitivity and subgroup analysis indicated that the results obtained in IL-10 categories were not stable.
CONCLUSIONSData from our meta-analysis supported the existence of a relationship between high serum IL-10 levels and adverse events in patients with ACS. Large study with longer follow-up is needed to confirm the findings.